NCT00954291UnknownNot Applicable
An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects
Taipei Medical University WanFang Hospital1 site in 1 country8 target enrollmentStarted: July 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- AUC0-t, AUC0-µ, Cmax, Tmax, T1/2, and MRT in plasma were determined with granisetron concentrations by non-compartment methods.
Study Overview
Brief Summary
The objective of the study is to characterize the pharmacokinetic profile of granisetron patch after single administration to healthy subjects.
Detailed Description
The objective of the study is to characterize the pharmacokinetic profile of granisetron patch after single administration to healthy subjects.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
Eligibility Criteria
- Ages
- 20 Years to 40 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects must be male at the age of 20-40 years old in good health on the basis of medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations.
- •Vital signs (after 3 minutes resting in a upright position) which are within the following ranges: Ear body temperature between 35.0-37.5 °C.Systolic blood pressure, 90-140 mm Hg.Diastolic blood pressure, 50-90 mm Hg.Pulse rate, 50-90 bpm.Fasting blood glucose, < 100 mg/dL.
- •Body weight must be above 50 kg and within -20 to +20% of ideal body weight.
- •Able to sign informed consent prior to study.
- •Able to communicate well with the investigator and comply with the requirements of the study.
Exclusion Criteria
- •Use of any prescription medication within 14 days prior to dosing.
- •Use of over-the-counter medications or vitamins within 14 days prior to dosing.
- •Significant illness within 2 weeks prior to dosing.
- •Participation in any clinical investigation within 2 months prior to dosing or longer than required by local regulation.
- •Donate or loss more than 500 mL of blood within 3 months prior to dosing.
- •Presence of cardiovascular disease.
- •Presence of gastrointestinal disease.
- •Presence of asthma or lung disease.
- •Presence of liver disease, hepatitis B, hepatitis C or liver injury as indicated by an abnormal liver function profile such as GOT, GPT, g-GT, alkaline phosphatase, serum bilirubin, HBsAg, or Anti-HCV.
- •Presence of impaired renal function as indicated by abnormal creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria).
- •Presence of neurological disease.
- •Presence of psychiatrical disease.
- •Subject is known for HIV infected.
- •A known hypersensitivity to granisetron or its analogs.
- •History of drug or alcohol abuse within 12 months prior to dosing.
- •Permanent confinement to an institution.
- •Individuals are judged by the investigator or pharmacokineticist to be undesirable as subjects for other reasons.
Outcomes
Primary Outcomes
AUC0-t, AUC0-µ, Cmax, Tmax, T1/2, and MRT in plasma were determined with granisetron concentrations by non-compartment methods.
Time Frame: 7 days
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"Essential HypertensionType 2 Diabetes MellitusNCT06226727Boryung Pharmaceutical Co., Ltd52
Withdrawn
Phase 1
A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult ParticipantsHealthyNCT04712006Janssen Research & Development, LLC
Completed
Phase 1
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)NCT05364424Hoffmann-La Roche43
Completed
Phase 1
A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607Malaria, FalciparumNCT02737007GlaxoSmithKline6
Completed
Phase 1
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy AdultsHypertensionNCT06281132Chong Kun Dang Pharmaceutical51